Randomised, double-blind, placebo-controlled study of pivagabine in neurasthenia

G. Pizzolato, A. Cagnin, D. Mancia, P. Caffarra, S. Avanzi, S. Copelli, C. Ciappina, F. Lo Presti, P. G. Spilimbergo, E. D'Antonio, E. Di Costanzo, M. Matrango, P. Pastres, P. P. Urbani, M. Signorino, M. Simoncelli, L. Provinciali, L. Regnicolo, C. Albano, G. RoccatagliataV. Rubino, S. Cultrera, M. Fracassi

Research output: Contribution to journalArticlepeer-review


One hundred and eighteen patients with neurasthenia, as defined by ICD 10 (International Classification of Diseases), participated in a randomised, double-blind, placebo-controlled trial of pivagabine (4-[(2,2-dimethyl-1- oxopropyl)amino]butanoic acid, CAS 69542-93-4, Tonerg®). Pivagabine 1800 mg/d was administered orally for four weeks. At the end of the trial, active medication was significantly superior to placebo on the Clinical Global Impression (CGI) improvement of illness scale. In addition, pivagabine treatment reduced the physical and mental fatigability of patients, and increased their sense of well-being.

Original languageEnglish
Pages (from-to)1329-1331
Number of pages3
JournalArzneimittel-Forschung/Drug Research
Issue number11 SPEC.SECT.11A
Publication statusPublished - 1997


  • CAS 69542-93-4
  • Corticotropin releasing factor
  • Neurasthenia
  • Pivagabine, improvement of neurasthenia
  • Tonerg®

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Chemistry(all)
  • Pharmacology


Dive into the research topics of 'Randomised, double-blind, placebo-controlled study of pivagabine in neurasthenia'. Together they form a unique fingerprint.

Cite this